Compare RLMD & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLMD | EH |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | China |
| Employees | 17 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.9M | 679.5M |
| IPO Year | 2012 | 2019 |
| Metric | RLMD | EH |
|---|---|---|
| Price | $5.93 | $7.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $12.40 | ★ $22.47 |
| AVG Volume (30 Days) | ★ 925.0K | 715.6K |
| Earning Date | 05-08-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | $33.23 |
| Revenue Next Year | N/A | $73.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.52 | $8.95 |
| 52 Week High | $8.00 | $20.44 |
| Indicator | RLMD | EH |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 29.95 |
| Support Level | $5.68 | N/A |
| Resistance Level | $7.46 | $10.68 |
| Average True Range (ATR) | 0.41 | 0.55 |
| MACD | -0.14 | -0.09 |
| Stochastic Oscillator | 5.11 | 3.62 |
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.